about
Activation of the peripheral endocannabinoid system in human obesityAnandamide and vanilloid TRPV1 receptorsIn vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints.The complexities of the cardiovascular actions of cannabinoidsVascular effects of anandamide and N-acylvanillylamines in the human forearm and skin microcirculation.Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approachNewly emerging Ca2+ entry channel molecules that regulate the vascular tone.Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusionsAngiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors.Characterization of anandamide-stimulated cannabinoid receptor signaling in human ULTR myometrial smooth muscle cells.Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors.Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries.Evolving the concept of regulation of vascular tone in humans.AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide.The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints.Cytochrome P450 pathway contributes to methanandamide-induced vasorelaxation in rat aorta.Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors.Mechanisms of ADRF release from rat aortic adventitial adipose tissue.The group IV afferent neuron expresses multiple receptor alterations in cardiomyopathyic rats: evidence at the cannabinoid CB1 receptor.Cannabinoid modulation of electrically evoked pH and oxygen transients in the nucleus accumbens of awake rats.
P2860
Q24655297-FB4609F5-A3E1-4C64-8632-167E22ACC183Q24672354-12DCDD65-4ACD-4F68-BDD3-CCEF7FF498D7Q33304983-725DC23A-D51D-4787-B78C-8641F76E5EBCQ35047093-4DABE666-0A7D-4D7D-B75F-C615D98B8639Q35049157-57C64FEA-F39C-4981-BF26-B7ED7B774DE1Q35822367-57E57C8F-EF16-4175-8C29-260221CE4A69Q35842507-54EAB2C6-5B25-48BF-882C-D1B302D810C4Q36052772-933B7E10-BF9E-4C22-B012-E4501BC58FC2Q36225837-A5EB3BEE-A30D-416D-95B0-6B1DF05D8797Q37332431-4FBD7B98-7BEC-41EC-851A-C476D54EE448Q38028659-47D404E6-DF63-4447-AB8D-E2383535C9FDQ39300226-45ECE6B5-7368-4442-BD6E-8A35680ABA7DQ40401804-10632A41-F39D-452B-901F-9265725D5E2AQ40654914-1721FF67-3ABD-4B83-BEFB-83B9A400A6B5Q41854357-155E6331-F67D-4A11-9D43-6A9CF63BA092Q42918598-26B24B71-B2A4-4985-AC5A-2148CD3490C1Q43004564-4F79ED36-F6B4-45D8-B174-E1D06147AAB7Q44673737-07F95F3D-2A91-4CA3-909D-A08F5FC9E20CQ46862869-78A5EBA5-EFFC-4629-8901-F6A96B548A3AQ48547114-91631140-6636-47D3-A390-C0E0970020C8
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cardiovascular pharmacology of anandamide.
@ast
Cardiovascular pharmacology of anandamide.
@en
Cardiovascular pharmacology of anandamide.
@nl
type
label
Cardiovascular pharmacology of anandamide.
@ast
Cardiovascular pharmacology of anandamide.
@en
Cardiovascular pharmacology of anandamide.
@nl
prefLabel
Cardiovascular pharmacology of anandamide.
@ast
Cardiovascular pharmacology of anandamide.
@en
Cardiovascular pharmacology of anandamide.
@nl
P921
P356
P1476
Cardiovascular pharmacology of anandamide.
@en
P2093
Edward D Högestätt
P M Zygmunt
P304
P356
10.1054/PLEF.2001.0346
P577
2002-02-01T00:00:00Z